Christopher R Flowers

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma
    Christopher R Flowers
    Lymphoma Clinic, Bone Marrow and Stem Cell Transplantation, Winship Cancer Institute, 1365 Clifton Road, N E Building C, Suite 3006, Emory University, Atlanta, GA 30322, USA
    Expert Rev Vaccines 6:307-17. 2007
  2. doi request reprint Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics
    Jie Li
    Winship Cancer Institute, Department of Hematology Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Transfusion 51:2175-82. 2011
  3. doi request reprint Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States
    Christopher R Flowers
    Department of Hematology Oncology, School of Medicine, Emory University, Atlanta, GA 30322, USA
    Cancer Epidemiol Biomarkers Prev 21:1520-30. 2012
  4. doi request reprint A decade of progress in lymphoma: advances and continuing challenges
    Christopher R Flowers
    Lymphoma Program, Winship Cancer Institute, Emory University, 1365 Clifton Road, Atlanta, GA 30322, USA
    Clin Lymphoma Myeloma Leuk 10:414-23. 2010
  5. doi request reprint Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation
    Hongzheng Zhang
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, 1365B Clifton Road NE, Atlanta, GA 30322, USA
    Biol Blood Marrow Transplant 18:1287-94. 2012
  6. doi request reprint A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas
    Rajni Sinha
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer 118:3538-48. 2012
  7. doi request reprint Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States
    Pareen J Shenoy
    Winship Cancer Institute Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Clin Lymphoma Myeloma Leuk 11:498-506. 2011
  8. doi request reprint A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma
    Jonathan L Kaufman
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Transfusion 53:76-84. 2013
  9. doi request reprint A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study
    Sagar Lonial
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 16:5079-86. 2010
  10. doi request reprint Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma
    R Donald Harvey
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
    Biol Blood Marrow Transplant 19:1393-5. 2013

Collaborators

Detail Information

Publications42

  1. ncbi request reprint BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma
    Christopher R Flowers
    Lymphoma Clinic, Bone Marrow and Stem Cell Transplantation, Winship Cancer Institute, 1365 Clifton Road, N E Building C, Suite 3006, Emory University, Atlanta, GA 30322, USA
    Expert Rev Vaccines 6:307-17. 2007
    ....
  2. doi request reprint Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics
    Jie Li
    Winship Cancer Institute, Department of Hematology Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Transfusion 51:2175-82. 2011
    ..Plerixafor is a recently Food and Drug Administration (FDA)-approved CXCR4 antagonist, which is combined with granulocyte-colony-stimulating factor (G-CSF) to facilitate stem cell mobilization of lymphoma and myeloma patients...
  3. doi request reprint Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States
    Christopher R Flowers
    Department of Hematology Oncology, School of Medicine, Emory University, Atlanta, GA 30322, USA
    Cancer Epidemiol Biomarkers Prev 21:1520-30. 2012
    ..In 2002, randomized trials changed this standard by showing that adding rituximab immunotherapy to CHOP improved survival. However, how these results influenced chemoimmunotherapy adoption in clinical practice remains unclear...
  4. doi request reprint A decade of progress in lymphoma: advances and continuing challenges
    Christopher R Flowers
    Lymphoma Program, Winship Cancer Institute, Emory University, 1365 Clifton Road, Atlanta, GA 30322, USA
    Clin Lymphoma Myeloma Leuk 10:414-23. 2010
    ....
  5. doi request reprint Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation
    Hongzheng Zhang
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, 1365B Clifton Road NE, Atlanta, GA 30322, USA
    Biol Blood Marrow Transplant 18:1287-94. 2012
    ..In lymphoma patients undergoing ASCT, PK-directed i.v. or oral busulfan-based conditioning regimens have comparable toxicity and OS...
  6. doi request reprint A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas
    Rajni Sinha
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer 118:3538-48. 2012
    ..A phase 1 study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone (R-CHOP) was conducted in patients with untreated follicular lymphoma (FL) and other indolent NHLs...
  7. doi request reprint Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States
    Pareen J Shenoy
    Winship Cancer Institute Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Clin Lymphoma Myeloma Leuk 11:498-506. 2011
    ..Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the United States, and prolymphocytic leukemia (PLL) is a related, rare chronic lymphoproliferative disorder...
  8. doi request reprint A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma
    Jonathan L Kaufman
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Transfusion 53:76-84. 2013
    ..Previous reports suggested that rituximab may impair stem cell collection and posttransplant engraftment in lymphoma patients undergoing autologous hematopoietic progenitor cell transplantation...
  9. doi request reprint A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study
    Sagar Lonial
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 16:5079-86. 2010
    ..We did a randomized phase I/II trial designed to evaluate the safety and efficacy of combining the proteasome inhibitor bortezomib with high-dose melphalan as the conditioning for high-dose therapy and autologous transplant for myeloma...
  10. doi request reprint Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma
    R Donald Harvey
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
    Biol Blood Marrow Transplant 19:1393-5. 2013
    ..Hematopoietic engraftment after transplantation and adverse events were similar to previous studies. Plerixafor given 17 hours before apheresis yields desired HSC collection efficiencies after induction treatment in myeloma patients...
  11. doi request reprint Examining racial differences in diffuse large B-cell lymphoma presentation and survival
    Christopher R Flowers
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
    Leuk Lymphoma 54:268-76. 2013
    ..61, p = 0.01). Future studies should examine biological differences that may underlie the observed racial differences in presentation and outcome...
  12. doi request reprint Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?
    Pareen Shenoy
    Emory University School of Medicine, Atlanta, GA, USA
    Clin Lymphoma Myeloma Leuk 10:270-7. 2010
    ....
  13. doi request reprint A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation
    Heather Renfroe
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Transfusion 51:1779-83. 2011
    ....
  14. doi request reprint Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma
    Rajni Sinha
    Winship Cancer Institute, Hematology and Medical Oncology, Emory University, School of Medicine, Atlanta, GA
    Clin Lymphoma Myeloma Leuk 13:657-63. 2013
    ..Our phase I study of cytarabine combined with fixed doses of vinorelbine, paclitaxel, etoposide, and cisplatin (VTEPA) for patients with R/R lymphoma showed an overall response rate (ORR) of 33%...
  15. doi request reprint Using primary site as a predictor of survival in mantle cell lymphoma
    Alexander J Ambinder
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    Cancer 119:1570-7. 2013
    ..We examined the association between primary disease site and survival in MCL patients to identify subgroups with distinct characteristics...
  16. doi request reprint Incidence and survival patterns of cutaneous T-cell lymphomas in the United States
    Muhammad Hassaan Imam
    Department of Internal Medicine, Emory University, Atlanta, GA, USA
    Leuk Lymphoma 54:752-9. 2013
    ..06, 95% CI 3.66-10.05) predicted worse survival for patients with MF/SS. Additional research identifying reasons for these differences are necessary to better understand these diseases and for new strategies in the treatment of CTCL...
  17. doi request reprint Idiotype vaccine strategies for treatment of follicular lymphoma
    Hemchandra Mahaseth
    Department of Hematology Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE Building B, Suite 4302, Atlanta, GA 30322, USA
    Future Oncol 7:111-22. 2011
    ....
  18. doi request reprint A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma
    Adam C Rose
    Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA 30322, USA
    Clin Lymphoma Myeloma Leuk 12:393-9. 2012
    ..We conducted a systematic literature review and meta-analyses to quantify the benefits of consolidative RIT...
  19. doi request reprint Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline
    Christopher R Flowers
    Emory University School of Medicine, Atlanta, GA, USA
    J Clin Oncol 31:794-810. 2013
    ..To provide guidelines on antimicrobial prophylaxis for adult neutropenic oncology outpatients and on selection and treatment as outpatients of those with fever and neutropenia...
  20. doi request reprint Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature
    Ajay Nooka
    Winship Cancer Institute Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Clin Lymphoma Myeloma Leuk 11:379-84. 2011
    ....
  21. doi request reprint Patterns of social support among lymphoma patients considering stem cell transplantation
    Roni Glover
    Department of Hematology Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Soc Work Health Care 50:815-27. 2011
    ..Future studies should test the impact of social support on health outcomes especially among the underserved population...
  22. ncbi request reprint Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation
    Mary J Ninan
    Atlanta Medical Center, Atlanta, Georgia 30322, USA
    Biol Blood Marrow Transplant 13:895-904. 2007
    ....
  23. doi request reprint Improving outcomes for patients with diffuse large B-cell lymphoma
    Christopher R Flowers
    Bone Marrow and Stem Cell Transplantation, Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    CA Cancer J Clin 60:393-408. 2010
    ....
  24. pmc Incidence patterns and outcomes for hodgkin lymphoma patients in the United States
    Pareen Shenoy
    Winship Cancer Institute, Emory University, 1365 Clifton Road, N E Building B, Suite 4302, Atlanta, GA 30322, USA
    Adv Hematol 2011:725219. 2011
    ..08, 95% CI 4.86-5.31). These current patterns for presentation and outcomes of HL help to delineate key populations in order to explore risk factors for HL and strategies to improve treatment outcomes...
  25. doi request reprint Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis
    Andrew M Evens
    Andrew M Evens, Tufts University School of Medicine, Boston Aimee Kroll Desrosiers, University of Massachusetts Medical School, Worcester, MA Ranjana Advani and Stavroula Otis, Stanford University Medical Center, Stanford, CA Oliver W Press and Linda M Parker, Fred Hutchinson Cancer Research Center, Seattle, WA Izidore S Lossos, Liat Nadav Dagan, and Jose Sandoval, University of Miami School of Medicine, Miami, FL Julie M Vose, University of Nebraska Medical Center, Omaha, NE Francisco J Hernandez Ilizaliturri, Roswell Park Cancer Institute, Buffalo Ramsey Abdallah and John P Leonard, Weill Cornell Medical College, New York, NY Barrett K Robinson, Indiana University School of Medicine, Indianapolis, IN Jessica L Yarber and Leo I Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL Kristie A Blum, The Ohio State University, Columbus, OH Christopher R Flowers, Emory University, Atlanta, GA Thomas M Habermann, Mayo Clinic, Rochester, MN and Nancy L Bartlett, Washington University School of Medicine, St Louis, MO
    J Clin Oncol 31:4132-9. 2013
    ..Lymphoma is the fourth most frequent cancer in pregnancy; however, current clinical practice is based largely on small series and case reports...
  26. doi request reprint The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy
    Loretta J Nastoupil
    Department of Hematology Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Expert Rev Anticancer Ther 13:1089-108. 2013
    ..A greater understanding of the actions of chemotherapies and targeted agents on cellular pathways will advance the development of rationally designed combinations corresponding to individual patients' disease profiles. ..
  27. doi request reprint Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma
    Catherine Bulka
    Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
    Cancer 119:3309-17. 2013
    ..An increased risk of non-Hodgkin lymphoma (NHL) has been observed among individuals with occupational exposure to benzene, but the risk among those living near benzene release sites has not been well described...
  28. doi request reprint Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase
    Disni Muringampurath-John
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
    Br J Haematol 158:608-14. 2012
    ..In this uncommon DLBCL subgroup, anthracycline-based regimens with rituximab are associated with early morbidity and mortality, but yield approximately 50% 4-year survival...
  29. ncbi request reprint Racial differences in the incidence and outcomes for patients with hematological malignancies
    Christopher R Flowers
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Curr Probl Cancer 31:182-201. 2007
  30. ncbi request reprint Diffuse large B-cell lymphoma: current treatment approaches
    Loretta J Nastoupil
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Oncology (Williston Park) 26:488-95. 2012
    ..Such approaches will provide key opportunities for further advances in the treatment of DLBCL, given that chemotherapy intensification appears to provide limited additional benefits over the current standard of care...
  31. doi request reprint Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes
    Ebenezer David
    Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, School of Medicine, Atlanta, GA, USA
    Blood 116:5285-8. 2010
    ..Together, these data demonstrate that tipifarnib synergizes with bortezomib by inducing protein accumulation as a result of the uncoupling of the aggresome and autophagy pathways...
  32. doi request reprint Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States
    Abeer N Abouyabis
    Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA 30322, USA
    Leuk Lymphoma 49:2099-107. 2008
    ..The variance in incidence rates and outcomes across PTCL subtypes support the pursuit of ongoing research to identify the etiology, pathophysiology, treatment patterns and differences in treatment response for PTCL subsets...
  33. ncbi request reprint Idiotype vaccine strategies for improving outcomes in follicular lymphoma
    Rajni Sinha
    Emory University, Atlanta, GA 30322, USA
    Expert Opin Biol Ther 8:1213-23. 2008
    ..Preclinical models and clinical studies demonstrate that immunizing FL patients against their own tumor idiotype induces humoral and cellular immunity and supresses tumor growth...
  34. pmc Development of the Lymphoma Enterprise Architecture Database: A caBIG(tm) Silver level compliant System
    Taoying Huang
    Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA
    Cancer Inform 8:45-64. 2009
    ..This illustrates the central importance of caBIG to the management of clinical and biological data...
  35. pmc Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population
    Susan G Moore
    Department of Hematology and Oncology, School of Medicine, Winship Cancer Institute, Emory University, Atlanta, USA
    BMC Health Serv Res 9:9. 2009
    ..However, the specificity of breast MRI is variable and costs are high. The purpose of this study was to determine if breast MRI is a cost-effective approach for the detection of breast cancer among young women at high risk...
  36. ncbi request reprint Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience
    Martha L Arellano
    Emory University Winship Cancer Institute, Atlanta, Georgia, USA
    Biol Blood Marrow Transplant 13:116-23. 2007
    ..Our study highlights the need for clinical trials in this area. Therapy with granulocyte-macrophage colony stimulating factor and interferon-alpha-2b is promising and will be pursued in a prospective trial at our center...
  37. doi request reprint Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease
    Mojtaba Akhtari
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, Georgia 30322, USA
    Transfusion 50:2424-31. 2010
    ..This hypothesis was tested by correlating numbers of DC precursors and T cells in the blood before and during ECP therapy with response of cGVHD...
  38. pmc Clinical, molecular, and environmental risk factors for hodgkin lymphoma
    Alison Maggioncalda
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Adv Hematol 2011:736261. 2011
    ..Understanding the relative importance of each of these findings and their links to HL development and survival will help clinical researchers expand curative therapies and create preventative strategies for HL...
  39. pmc Development of query strategies to identify a histologic lymphoma subtype in a large linked database system
    Michael Graiser
    Emory University School of Medicine, Winship Cancer Institute, Oncology Informatics, Atlanta, GA 30322, USA
    Cancer Inform 3:149-58. 2007
    ....
  40. doi request reprint Novel agents for diffuse large B-cell lymphoma
    Rajni Sinha
    Emory University, Winship Cancer Institute, School of Medicine, Atlanta, GA 30322, USA
    Expert Opin Investig Drugs 20:669-80. 2011
    ..Over the last decade, there has been an increasing exploration of novel therapies derived from improved understanding of DLBCL biology and tumor-host interactions...
  41. ncbi request reprint Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
    Razvan Diaconescu
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 104:1550-8. 2004
    ..In conclusion, nonmyeloablative regimens had lower RRT and NRM and could be considered for comparative studies, including younger patients with more favorable Charlson comorbidity scores...
  42. ncbi request reprint Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients
    Shannon T Kahn
    Department of Radiation Oncology, San Diego, California, USA
    Cancer J 11:425-31. 2005
    ....